Gemeinschaftsklinikum Mittelrhein gGmbH
- Address
- lock Available on a paid plan
Gemeinschaftsklinikum Mittelrhein gGmbH - Hematologic Malignancies Research Center
Gemeinschaftsklinikum Mittelrhein gGmbH is a clinical research center specializing in the treatment of complex hematologic malignancies. The center focuses on innovative therapeutic approaches for patients with high-risk blood cancers, particularly those requiring intensive treatment strategies and allogeneic stem cell transplantation.
- Acute myeloid leukemia (AML) with intermediate or poor-risk features according to ELN classification
- High-risk myelodysplastic neoplasia and related hematologic disorders
- Novel immunotherapy combinations with intensive chemotherapy regimens
- Allogeneic stem cell transplantation for high-risk hematologic conditions
The center is actively investigating magrolimab, a cutting-edge immunotherapeutic agent, in combination with intensive chemotherapy for newly diagnosed AML patients. This research emphasizes achieving optimal complete remission rates (CR/CRi/CRh) during induction therapy to improve outcomes for patients with ELN intermediate or poor-risk disease who are candidates for allogeneic stem cell transplantation, representing a commitment to advancing treatment options for the most challenging hematologic malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 75 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 74 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 16 by active trials.
lock +15 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gemeinschaftsklinikum Mittelrhein gGmbH
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy of Ponatinib vs. Imatinib with Low-Intensity Chemotherapy in Adults with De Novo Ph+ Acute Lymphoblastic Leukemia | Goethe University Frankfurt | Phase II | Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 75 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 10 | Unknown | 2015-06-02 | 2025-05-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.